BRAF Mutation Analysis in Fine-Needle Aspiration Cytology of Fixed Slide Specimens in Patients with Papillary Thyroid Carcinoma

Overview

Journal Med J Islam Repub Iran

Specialty General Medicine

Date 2024 Dec 16

PMID 39678775

Authors

Sara Cheraghi

Maryam Honardoost

Fereshteh Abdolmaleki

Mohammad E Khamseh

Affiliations

Soon will be listed here.

Abstract

Background: Papillary thyroid carcinoma is the most frequent type of thyroid cancer. The BRAF mutation is associated with tumor progression. We explored the utility of the BRAF molecular testing on fine needle aspiration fixed specimens of patients with confirmed diagnoses of papillary thyroid carcinoma.

Methods: Fixed thyroid cytology slide specimens of 19 patients with Bethesda II to VI reports were used to detect BRAF mutation by pyrosequencing of extracted DNA.

Results: BRAF mutation was detected in 25% of the specimens with Bethesda category III and IV nodules and in 73% of the nodules with Bethesda category V and VI.

Conclusion: BRAF mutation analysis can be performed on fixed fine needle aspiration cytology specimens. Although the frequency of the mutation is higher in specimens with higher Bethesda category scores, it could support clinical decision-making in thyroid nodules with intermediate Bethesda category scores.

References

Henke L, Pfeifer J, Baranski T, DeWees T, Grigsby P . Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma. Endocr Connect. 2018; 7(12):1226-1235. PMC: 6240143. DOI: 10.1530/EC-18-0264. View

Dominguez Ayala M, Exposito Rodriguez A, Bilbao Gonzalez A, Minguez Gabina P, Gutierrez Rodriguez T, Rodeno Ortiz de Zarate E . BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (I) therapy: Should we modify our therapeutic strategy?. Cir Esp (Engl Ed). 2018; 96(5):276-282. DOI: 10.1016/j.ciresp.2018.02.018. View

Oh H, Kwon H, Park S, Kim M, Jeon M, Kim T . Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm. Endocrinol Metab (Seoul). 2018; 33(1):62-69. PMC: 5874197. DOI: 10.3803/EnM.2018.33.1.62. View

Pinzani P, Santucci C, Mancini I, Simi L, Salvianti F, Pratesi N . BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin Chim Acta. 2011; 412(11-12):901-5. DOI: 10.1016/j.cca.2011.01.014. View

Loo E, Khalili P, Beuhler K, Siddiqi I, Vasef M . BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2017; 26(10):709-713. DOI: 10.1097/PAI.0000000000000516. View

Kim D, Song K, Kim S . High prevalence of carcinoma in ultrasonography-guided fine needle aspiration cytology of thyroid nodules. Endocr J. 2008; 55(1):135-42. DOI: 10.1507/endocrj.k07-120. View

Long G, Menzies A, Nagrial A, Haydu L, Hamilton A, Mann G . Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011; 29(10):1239-46. DOI: 10.1200/JCO.2010.32.4327. View

Mauger F, How-Kit A, Tost J . COLD-PCR Technologies in the Area of Personalized Medicine: Methodology and Applications. Mol Diagn Ther. 2017; 21(3):269-283. DOI: 10.1007/s40291-016-0254-8. View

Marotta V, Chiofalo M, Di Gennaro F, Daponte A, Sandomenico F, Vallone P . Kinase-inhibitors for iodine-refractory differentiated thyroid cancer: still far from a structured therapeutic algorithm. Crit Rev Oncol Hematol. 2021; 162:103353. DOI: 10.1016/j.critrevonc.2021.103353. View

10.

Marchetti I, Lessi F, Mazzanti C, Bertacca G, Elisei R, Di Coscio G . A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009; 19(8):837-42. DOI: 10.1089/thy.2009.0074. View

11.

Titov S, Ivanov M, Demenkov P, Katanyan G, Kozorezova E, Malek A . Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears. BMC Cancer. 2019; 19(1):1010. PMC: 6819494. DOI: 10.1186/s12885-019-6154-7. View

12.

Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M . Update on Fundamental Mechanisms of Thyroid Cancer. Front Endocrinol (Lausanne). 2020; 11:102. PMC: 7082927. DOI: 10.3389/fendo.2020.00102. View

13.

Al-Masri M, Al-Shobaki T, Al-Najjar H, Iskanderian R, Younis E, Abdallah N . BRAF V600E mutation in papillary thyroid carcinoma: it's relation to clinical features and oncologic outcomes in a single cancer centre experience. Endocr Connect. 2021; 10(12):1531-1537. PMC: 8679880. DOI: 10.1530/EC-21-0410. View

14.

Ohori N, Singhal R, Nikiforova M, Yip L, Schoedel K, Coyne C . BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol. 2012; 121(4):197-205. DOI: 10.1002/cncy.21229. View

15.

Zablocka T, Kreismane M, Pjanova D, Isajevs S . Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncol Lett. 2022; 25(1):27. PMC: 9713804. DOI: 10.3892/ol.2022.13613. View

16.

Laurini J, Aoun P, Iqbal J, Chan W, Greiner T . Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders. Am J Clin Pathol. 2012; 138(6):877-83. DOI: 10.1309/AJCP5TWORA0TMXGL. View

17.

Silver J, Bogatchenko M, Pusztaszeri M, Forest V, Hier M, Yang J . BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm. J Otolaryngol Head Neck Surg. 2021; 50(1):63. PMC: 8572458. DOI: 10.1186/s40463-021-00543-9. View

18.

Kim S, Lee J, Kim J, Ki C, Oh Y, Choi Y . BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab. 2010; 95(8):3693-700. DOI: 10.1210/jc.2009-2795. View

19.

Czarniecka A, Oczko-Wojciechowska M, Barczynski M . mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg. 2016; 5(5):495-505. PMC: 5106385. DOI: 10.21037/gs.2016.09.09. View

20.

Sapio M, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G . Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol. 2006; 154(2):341-8. DOI: 10.1530/eje.1.02072. View